Purdue Pharma Faces Criminal Charges and Civil Settlements
Purdue Pharma agrees to plead guilty to criminal charges filed against it for marketing and distributing its highly addictive painkillers. This is part of the $8 billion settlement lobbed against the drug manufacturer.
Purdue Pharma is expected to plead guilty to three felonies, which includes one count of dual-object conspiracy to defraud the U.S. and violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Federal Anti-Kickback Statute.
The company is expected to admit to marketing opioids to more than 100 doctors who are suspected of writing illegal prescriptions and not telling the federal Drug Enforcement Administration (DEA).
Do you have information that may affect the class action lawsuit? Feel free to contact us today.
Purdue Pharma Opioid Settlement Details
The settlement includes a $3.54 billion criminal fine and a $2 billion in criminal forfeiture, the largest amount of criminal penalties to be levied against a pharmaceutical manufacturer. The company is also charged to pay $2.8 billion in a civil settlement, which brings the total penalties to $8.3 billion.
Purdue Pharma, however, is currently in the middle of ongoing bankruptcy proceedings, which means that the company will highly unlikely pay anything close to the $8.3 billion in the settlement deal.
Company owners, members of the Sackler family, have agreed to pay $225 million in civil penalties but does not release them from criminal liability and the ongoing criminal investigation.
The company is accused of approving a new marketing program in 2013 that intensifies OxyContin marketing to high-volume prescribers, despite being aware of the contracted legitimate market for Purdue Pharma’s opioids. This, however, led health care providers to prescribe opioids for uses that were “unsafe, ineffective, and medically unnecessary, and that often led to abuse and diversion.”
Opioid drugs such as OxyContin are commonly used in the medical field to manage pain after surgery or injuries. These drugs are effective yet also highly addictive, which can lead to irresponsible opioid prescriptions or the use of street-drug opioids, such as heroin.
According to Gary L. Cantrell, Deputy Inspector General for Investigations at the U.S. Department of Health and Human Services’ Office of Inspector General, the “opioid epidemic remains a significant public health challenge that impacts the lives of men and women across the country. Unfortunately, Purdue’s reckless actions and violation of the law senselessly risked patients’ health and well-being. With our law enforcement partners, we will continue to combat the opioid crisis, including holding the pharmaceutical industry and its executives accountable.”
If you’re affected by the Purdue Pharma OxyContin Opioid lawsuit settlement, we’d love to hear from you.
Editor’s note on the Purdue Pharma Opioid Settlement:
This piece is written about the recent Purdue Pharma OxyContin Opioid Class Action Settlement. If you are considered eligible to be among the class of consumers described in the class action lawsuit settlement, you may eventually be able to participate in receiving any compensation the court may award.
If you believe that what is alleged in the Purdue Pharma OxyContin Opioid class action settlement has affected you, please don’t hesitate to reach out to us.
We’d be happy to help you take a step in the right direction, fight this issue, and better enable you to join the consumer class action. If interested, please send an email to Outreach@ConsiderTheConsumer.com, find us on Twitter or Facebook, or even connect with us directly on our website! We look forward to hearing from you all.
Similarly, please check out our current list of Class Actions and Class Action Investigations, here.
Interested in articles like these? Become a subscriber below!